Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
复制标题
DOI：
10.1200/jco.19.00818
复制
发表时间：
2020-01-20
影响因子：
45.3
通讯作者：
Flaherty, Keith T.
中科院分区：
文献类型：
--
作者：
Azad, Nilofer S.;Gray, Robert J.;Flaherty, Keith T.
国家癌症研究所分子分析治疗选择（NCI-MATCH）试验是迄今为止最大的复发性或难治性恶性肿瘤患者的国家精确肿瘤学研究（> 1，100个站点），根据肿瘤分子改变将患者分配到平行的II期研究中的靶向治疗。抗程序性死亡受体1抑制剂nivolumab先前在错配修复（MMR）缺陷型结肠癌中显示出活性。我们假设纳武利尤单抗对MMR缺陷的非结直肠肿瘤患者具有活性。患者和方法患有复发性或难治性肿瘤、终末器官功能良好以及东部肿瘤协作组体力状况的合格患者
PURPOSE The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest national precision oncology study to date (> 1,100 sites) of patients with relapsed or refractory malignancies, assigned patients to targeted therapy in parallel phase II studies based on tumor molecular alterations. The anti-programmed death receptor 1 inhibitor nivolumab previously showed activity in mismatch repair (MMR)-deficient colon cancer. We hypothesized that nivolumab would have activity in patients with MMR-deficient, noncolorectal tumors.PATIENTS AND METHODS Eligible patients with relapsed or refractory tumors, good end-organ function, and Eastern Cooperative Oncology Group performance status of